Intellia Therapeutics and Novartis Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing in Additional...
December 06 2018 - 7:30AM
– Intellia’s Right to Use Proprietary Lipid Nanoparticle
Technology Extended to All Settings– Intellia Will Receive a
One-time $10 Million Payment
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing
company focused on developing curative therapeutics using
CRISPR/Cas9 technology both in vivo and ex vivo, announced an
expansion of its existing cell therapy collaboration with Novartis,
to include the ex vivo development of innovative cell therapies
using certain ocular stem cells. As part of the updated
collaboration terms, Novartis will have the right to develop
CRISPR/Cas9-based products for one or more targets using these stem
cells. Intellia will receive a one-time $10 million cash payment
and, consistent with the original collaboration agreement, Intellia
also is eligible to receive downstream success-based milestones and
royalties.
With the collaboration expansion announced today, Intellia will
gain expanded rights to Novartis’ lipid nanoparticle (LNP)
technology for all genome editing applications in both in vivo and
ex vivo settings. This licensed LNP technology is the foundation of
Intellia’s proprietary modular delivery system of CRISPR/Cas9 for
its in vivo product pipeline. Intellia retains rights to all other
in vivo and ex vivo applications of CRISPR/Cas9, including for eye
disorders, subject to certain in vivo target selection options by
Novartis set forth in the original agreement.
“Genome editing enhancements made by CRISPR/Cas9 will enable the
next generation of cell therapies. With our collaborator, Novartis,
we are broadening the ex vivo application of our CRISPR/Cas9
technology from hematopoietic stem cells, or HSCs, to ocular stem
cells. We are pleased to expand our relationship with Novartis, and
to continue to work together to develop cell therapies,” said
Intellia President and Chief Executive Officer John Leonard, M.D.
“Broader rights to Novartis’ LNP technology will assist our efforts
to apply this technology in ex vivo settings for the development of
proprietary cell therapies, just as we have done to develop our
proprietary modular delivery system for in vivo products in the
liver and other organs.”
About the Novartis/Intellia Agreement
Under the terms of the original agreement, Novartis received
exclusive rights to develop all collaboration programs focused on
engineered chimeric antigen receptor T cells (CARTs), while both
companies committed to advancing their respective hematopoietic
stem cell (HSC) programs. The work of these preclinical programs,
including for sickle cell disease, is ongoing. The discovery
and development collaboration, including the updates announced
today, is set to expire in December 2019.
About Intellia’s Ex Vivo Programs
Independent from its ex vivo collaboration with Novartis,
Intellia also is advancing its wholly owned ex vivo pipeline of
immuno-oncology and autoimmune cell therapies. Intellia’s
proprietary ex vivo programs include its acute myeloid leukemia
(AML) program utilizing transgenic T cell receptors (TCRs) against
Wilms’ Tumor 1 (WT1), a target identified in collaboration with
Ospedale San Raffaele (OSR).
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company
focused on developing proprietary, curative therapeutics using the
CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology
has the potential to transform medicine by permanently editing
disease-associated genes in the human body with a single treatment
course, and through improved cell therapies that can treat cancer
and immunological diseases, or can replace patients’ diseased
cells. The combination of deep scientific, technical and clinical
development experience, along with its leading intellectual
property portfolio, puts Intellia in a unique position to unlock
broad therapeutic applications of the CRISPR/Cas9 technology and
create a new class of therapeutic products. Learn more about
Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com and follow
us on Twitter @intelliatweets.
Forward-Looking StatementsThis press release
contains “forward-looking statements” of Intellia Therapeutics,
Inc. (“Intellia”) within the meaning of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements
include, but are not limited to, express or implied statements
regarding our ability to advance and expand the CRISPR/Cas9
technology to develop into human therapeutic products; our
CRISPR/Cas9 intellectual property portfolio; the potential timing
and advancement of our preclinical studies, including for our
internal or partnered programs; the potential development of our
proprietary lipid nanoparticle (“LNP”) delivery system; the
potential development of our in vivo or ex vivo cell
therapeutics of all types using CRISPR/Cas9 technology, including
therapies targeting Wilms’ Tumor 1 (“WT1”) in particular; the
intellectual property position and strategy of Intellia’s licensors
or other parties from which it derives rights, as well as
third-parties and competitors; and the potential timing and receipt
of future milestones and royalties based on Intellia’s
collaboration with Novartis.
Any forward-looking statements in this presentation are based on
management’s current expectations and beliefs of future events, and
are subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks
and uncertainties include, but are not limited to: risks related to
Intellia’s ability to protect and maintain our intellectual
property position; risks related to the ability of our licensors to
protect and maintain their intellectual property position;
uncertainties related to the initiation and conduct of studies and
other development requirements for our product candidates; the risk
that any one or more of Intellia’s product candidates will not be
successfully developed and commercialized; the risk that the
results of preclinical studies will not be predictive of future
results in connection with future studies; the risk that Intellia’s
collaborations with Novartis will not continue or will not be
successful; and risks related to the competitive landscape. For a
discussion of these and other risks and uncertainties, and other
important factors, any of which could cause Intellia’s actual
results to differ from those contained in the forward-looking
statements, see the section entitled “Risk Factors” in Intellia’s
most recent annual report on Form 10-K and quarterly reports on
Form 10-Q filed with the Securities and Exchange Commission, as
well as discussions of potential risks, uncertainties, and other
important factors in Intellia’s other filings with the Securities
and Exchange Commission. All information in this presentation is as
of the date of the release, and Intellia Therapeutics undertakes no
duty to update this information unless required by law.
Intellia
Contacts:Media:Jennifer Mound
Smoter
Senior Vice
President
External Affairs & Communications
+1 857-706-1071
jenn.smoter@intelliatx.com
Lynnea OlivarezAssociate DirectorExternal Affairs &
Communications+1 956-330-1917
lynnea.olivarez@intelliatx.com
Investors:Lindsey TrickettVice
PresidentInvestor Relations+1
857-285-6211lindsey.trickett@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Oct 2023 to Oct 2024